Antonio Salar

Summary

Affiliation: Hospital del Mar
Country: Spain

Publications

  1. ncbi High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma
    Antonio Salar
    Department of Clinical Hematology from Hospital del Mar, Hospital de la Santa Cruz y San Pablo, Hospital Germans Trias i Pujol, Hospital Clinic, Barcelona, Spain
    Haematologica 87:1028-35. 2002
  2. ncbi Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease
    Antonio Salar
    Gut 56:1169-70. 2007
  3. ncbi Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type
    Antonio Salar
    Department of Clinical Hematology, Hospital Universitari del Mar, Barcelona, Spain
    Cancer 115:5210-7. 2009
  4. ncbi Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study
    Antonio Salar
    Department of Clinical Hematology, Hospital del Mar, Barcelona, Spain
    Am J Surg Pathol 30:1274-80. 2006
  5. ncbi Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution
    Antonio Salar
    Department of Clinical Hematology, Hospital del Mar, Barcelona, Spain
    Eur J Haematol 77:338-40. 2006
  6. ncbi NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma
    Eva Gimeno
    Department of Clinical Hematology, Hospital Universitari del Mar, Barcelona, Spain
    Leuk Res 35:715-20. 2011
  7. ncbi Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients
    Carlos Besses
    Haematology Department Cancer Research Program Pathology Department, IMIM Hospital del Mar Universitat Autònoma de Barcelona Methodological Consulting in Biomedical Research, Biomedical Research Park Universitat Pompeu Fabra, Barcelona, Spain
    Br J Haematol 152:413-9. 2011
  8. ncbi Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma
    Eva Gimeno
    Department of Clinical Hematology, Hospital del Mar, Barcelona, Spain
    Leuk Res 35:358-62. 2011
  9. ncbi FOXP1 status in splenic marginal zone lymphoma: a fluorescence in situ hybridization and immunohistochemistry approach
    Cristina Baro
    Dept Biologia Animal, Vegetal i Ecologia Unitat d Antropologia Biològica Facultat de Biociències Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain
    Histol Histopathol 24:1399-404. 2009
  10. ncbi The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice
    Antonio Salar
    Haematology Department, Hospital del Mar, Barcelona, Spain
    Leuk Res 36:548-53. 2012

Collaborators

Detail Information

Publications26

  1. ncbi High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma
    Antonio Salar
    Department of Clinical Hematology from Hospital del Mar, Hospital de la Santa Cruz y San Pablo, Hospital Germans Trias i Pujol, Hospital Clinic, Barcelona, Spain
    Haematologica 87:1028-35. 2002
    ..A salvage program including infusional high-dose ifosfamide plus etoposide (IFOVM) was evaluated in patients with refractory or relapsed aggressive non-Hodgkin's lymphoma...
  2. ncbi Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease
    Antonio Salar
    Gut 56:1169-70. 2007
  3. ncbi Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type
    Antonio Salar
    Department of Clinical Hematology, Hospital Universitari del Mar, Barcelona, Spain
    Cancer 115:5210-7. 2009
    ..Currently, there are no consensus guidelines regarding the best therapeutic option for patients with extranodal marginal zone lymphomas of the mucosa-associated lymphoid tissue (MALT) type...
  4. ncbi Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study
    Antonio Salar
    Department of Clinical Hematology, Hospital del Mar, Barcelona, Spain
    Am J Surg Pathol 30:1274-80. 2006
    ..IHC for cyclin D1 was significantly more sensitive than FISH t(11;14) or PCR for immunoglobulin heavy chain gene to confirm MCL in this setting...
  5. ncbi Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution
    Antonio Salar
    Department of Clinical Hematology, Hospital del Mar, Barcelona, Spain
    Eur J Haematol 77:338-40. 2006
    ..Only, three patients developed symptoms, all grade 1. In conclusion, rituximab administration in a 90-min infusion schedule is well tolerated and safe, both in patients who are administered steroids and in patients who are not...
  6. ncbi NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma
    Eva Gimeno
    Department of Clinical Hematology, Hospital Universitari del Mar, Barcelona, Spain
    Leuk Res 35:715-20. 2011
    ..These findings suggest that NT-proBNP ≥ 900 pg/ml could be considered a useful marker for risk assessment in NHL patients treated with chemotherapy...
  7. ncbi Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients
    Carlos Besses
    Haematology Department Cancer Research Program Pathology Department, IMIM Hospital del Mar Universitat Autònoma de Barcelona Methodological Consulting in Biomedical Research, Biomedical Research Park Universitat Pompeu Fabra, Barcelona, Spain
    Br J Haematol 152:413-9. 2011
    ..In conclusion, first-line HU can attain PMR in more than 50% of newly diagnosed PV and ET patients, with a continuous decrease of the JAK2 V617F allele burden in PV patients during treatment...
  8. ncbi Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma
    Eva Gimeno
    Department of Clinical Hematology, Hospital del Mar, Barcelona, Spain
    Leuk Res 35:358-62. 2011
    ..NPLD at intermediate doses (30mg/m(2)) is effective and well tolerated in these patients. In addition, NT-proBNP levels > 900ng/ml at diagnosis have demonstrated to be a good predictor for OS and PFS in this cohort of patients...
  9. ncbi FOXP1 status in splenic marginal zone lymphoma: a fluorescence in situ hybridization and immunohistochemistry approach
    Cristina Baro
    Dept Biologia Animal, Vegetal i Ecologia Unitat d Antropologia Biològica Facultat de Biociències Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain
    Histol Histopathol 24:1399-404. 2009
    ..FOXP1 protein expression seemed to be not related to any aberration and IHC studies are not conclusive...
  10. ncbi The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice
    Antonio Salar
    Haematology Department, Hospital del Mar, Barcelona, Spain
    Leuk Res 36:548-53. 2012
    ..Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery...
  11. ncbi Granulomatous dermatitis with enlarged histiocytes: a characteristic pattern of granulocyte colony-stimulating factor. Report of two cases and review of the literature
    Marta Ferran
    Department of Dermatology, Hospital del Mar, IMAS, Passeig Maritim 25 29, ES 08003 Barcelona, Spain
    Dermatology 212:188-93. 2006
    ..This histopathological variant of granulomatous dermatitis with "enlarged histiocytes" seems to be characteristic of an unusual cutaneous reaction secondary to CSF treatment...
  12. ncbi Hypopituitarism associated with mycotic aneurysm of the cavernous carotid artery in a renal transplant recipient
    Maria Jose Carrera
    Department of Endocrinology, Hospital del Mar IMAS, Passeig Maritim 25 29, Barcelona 08003, Spain
    Nephrol Dial Transplant 21:3299-300. 2006
  13. ncbi New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY)
    Cristina Baro
    Department Biologia Animal, Vegetal i Ecologia, Unitat d Antropologia Biològica, Facultat de Biociencies, Universitat Autonoma de Barcelona, Bellaterra, Spain
    Leuk Res 32:727-36. 2008
    ..Del(7)(q22-q32) and trisomy 3/3q were the most common chromosomal aberrations. In addition, new translocations involving chromosomes 3, 6, 8, 9, 12 and 14q32 region were detected...
  14. ncbi Study of regulatory T-cells in patients with gastric malt lymphoma: influence on treatment response and outcome
    Mar Garcia
    Departments of Pathology, Hospital del Mar, Barcelona, Spain
    PLoS ONE 7:e51681. 2012
    ....
  15. ncbi Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical clinicopathological and immunophenotypical features
    Cristina Muniesa
    Department of Dermatology, Hospital de Viladecans, Barcelona, Spain
    J Am Acad Dermatol 66:650-4. 2012
    ..Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg type can eventually disseminate to extracutaneous sites including testes. In addition, patients with testicular lymphoma can develop specific skin involvement...
  16. ncbi Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients
    Alberto Alvarez-Larran
    Haematology Department, Hospital del Mar, IMIM, Barcelona, Spain
    Br J Haematol 146:504-9. 2009
    ..04). In conclusion, PPMF is a frequent complication in PV patients at 15 years with the risk being higher in patients with increased LDH, endogenous megakaryocytic colony formation or a high JAK2 V617F allele burden...
  17. ncbi Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease
    Eva Gonzalez-Barca
    Clinical Hematology Department, Hospital Duran i Reynals, Institut Catala d Oncologia, Av Gran Via s n Km 2, 7, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    Haematologica 92:1489-94. 2007
    ..The purpose of this trial was to evaluate the efficacy of treatment with extended doses of rituximab adapted to the response in patients with post-transplant lymphoproliferative disorders after solid organ transplantation...
  18. ncbi Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma
    Armando Lopez-Guillermo
    Hematology Department, Hospital Clinic de Barcelona, Barcelona, Spain
    Leuk Lymphoma 52:1-14. 2011
    ..These guidelines provide healthcare professionals with updated and consensual tools for the better management of patients with follicular lymphoma...
  19. ncbi Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma
    Blanca Espinet
    Laboratori de Citogenètica Molecular, Laboratori de Citologia Hematologica, Servei de Patologia, Servei d Hematologia Clinica, GRETNHE, IMIM Hospital del Mar, Barcelona, Spain
    Genes Chromosomes Cancer 49:439-51. 2010
    ..Additionally, we observed that 3q gains and 17p losses detected by conventional cytogenetics are proliferation-independent prognostic markers indicating poor outcome...
  20. ncbi Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group
    Marta Salido
    Hospital del Mar, IMAS, Barcelona, Spain
    Blood 116:1479-88. 2010
    ..Complexity of the karyotype, 14q aberrations, and TP53 deletions are poor prognostic indicators and may be considered together with other clinicobiologic parameters to ascertain the prognosis of SMZL...
  21. ncbi Successful dexrazoxane treatment of a potentially severe extravasation of concentrated doxorubicin
    David Conde-Estévez
    Department of Pharmacy, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
    Anticancer Drugs 21:790-4. 2010
    ..Anthracyclines can be administered using reduced occlusion infusion pumps, but it seems preferable to always administer a free-running infusion to minimize accidents like this one...
  22. ncbi Progressive painless swelling of glans penis: uncommon clinical manifestation of systemic non-Hodgkin's lymphoma
    Fernando Gallardo
    Department of Dermatology, Hospital Universitari del Mar, Autonomous University of Barcelona, Barcelona, Spain
    Urology 73:929.e3-5. 2009
    ..We report the case of a 74-year-old man presenting with progressive painless induration and swelling of the glans penis associated with mild preputial edema as the initial manifestation of systemic non-Hodgkin's lymphoma...
  23. ncbi Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab
    Antonio Salar
    J Clin Oncol 23:7361-2; author reply 7362-3. 2005
  24. ncbi Monoclonal cryoglobulinemia: the first manifestation of gastric marginal B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
    Eva Gimeno
    Leuk Res 30:1465-6. 2006
  25. ncbi Langerhans' cell histiocytosis mimicking relapse in a patient with follicular lymphoma
    Eva Gimeno
    Ann Hematol 87:675-6. 2008
  26. ncbi Persistent monoclonality after histological remission in gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy and/or surgery: influence of t(11;18)(q21;q21)
    Almudena Santon
    Department of Pathology, Hospital Ramon y Cajal, Madrid, Spain
    Leuk Lymphoma 49:1516-22. 2008
    ..The presence of t(11;18)(q21;q21) seems to condition long-term persistence of the initial lymphoma clone.trade mark...